Moffitt logo

Clinical Trials Search

Clinical Trial 19481

Cancer Type: Malignant Hematology
Study Type: Treatment
NCT#: NCT03190278

Phase: Phase I
Principal Investigator: Sallman, David

Call 813-745-6100
or 1-800-679-0775 Learn More
Overview

Study Title

Phase I, Open Label Dose-Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART123 (Allogeneic Engineered T Cells Expressing anti-CD123 Chimeric Antigen Receptor), Administered in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Summary

Phase I, first-in-human, open-label, dose-escalation and dose-expansion study evaluating the safety and efficacy of UCART targeting CD123 in patients with relapsed/refractory acute myeloid leukemia (AML). The purpose of this study is to evaluate the safety and clinical activity of one infusion of UCART123 and determine the Maximum Tolerated Dose (MTD).

Objective

Primary:  To assess the safety and tolerability of Universal Chimeric Antigen Receptor (CAR) T-cells targeting Cluster of Differentiation (CD) 123 (UCART123) administered to patients with relapsed/refractory and newly diagnosed highrisk acute myeloid leukemia (AML), and  To determine the Recommended Phase 2 Dose (RP2D) of UCART123. Secondary:  To assess the efficacy of UCART123 in relapsed or refractory AML patients and in patients with newly diagnosed, untreated AML (as defined by World Health Organization [WHO] criteria, [Arber et al., 2016]) who meet criteria for the European Leukemia Net (ELN) adverse genetics prognostic group (Döhner et al., 2016; Röllig et al., 2011). Exploratory:  To characterize the expansion, trafficking, and persistence of UCART123 after infusion by assessing the kinetics and characteristics of UCART123 at different time-points, in blood and bone marrow;  To assess cytokine, growth factor, and C-reactive protein levels after UCART123 infusion;  To investigate the development of an UCART123 generated immune response;  To investigate the potential relationship between baseline levels of CD123 expression and clinical outcome;  To assess the impact of UCART123 on leukemia stem cells, hematopoietic stem cells (HSCs), and progenitor cells;  To confirm the absence of replication competent lentivirus in blood;  To assess the impact of UCART123 on the tumor cell population by targeted sequencing; and  To monitor immune cell depletion and reconstitution post lymphodepletion and UCART123.

Treatments

Therapies

Chemotherapy (NOS); Immunotherapy; Therapy (NOS)

Medications

Alemtuzumab (); Campath (Alemtuzumab); Elitek (Rasburicase); Hydroxyurea (Droxia); Rasburicase (); Rituxan (rituximab); Tocilizumab (); UCART123v1 (); UCART123v1.2 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate); rituximab ()

Inclusion Criteria

  • Patients with relapsed or primary refractory AML (as defined in WHO criteria) with >5% bone marrow blasts
  • Patients with CD123+ blast cells (verified by flow cytometry)
  • Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of > Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period
  • (Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)
  • Other criteria may apply

  • Exclusion Criteria

  • Patients with APL or CNS Leukemia
  • Previous investigation gene or cell therapy (including CAR)
  • > 2 prior allogeneic SCTs
  • Prior treatment with rituximab or other anti-CD20 therapy within 3 months
  • Any known active or uncontrolled infection
  • Other criteria may apply

  • If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.